

RECORDATI REPORTS SIGNIFICANT GROWTH IN THE FIRST NINE MONTHS 2013. SALES +13.2%, OPERATING INCOME +12.0% AND NET INCOME +9.0%. INTERIM DIVIDEND € 0.22 PER SHARE.

- Consolidated revenue € 702.0 million, + 13.2%.
- EBITDA⁽¹⁾ € 174.0 million, + 15.4%
- Operating income € 148.3 million, + 12.0%.
- Net income € 101.5 million, + 9.0%.
- Net financial position⁽²⁾: net debt of € 133.3 million.
- Closing of the acquisition of a portfolio of drugs for the treatment of rare and other diseases in the U.S.A..
- Agreements signed for the acquisition of Opalia Pharma S.A., a Tunisian pharmaceutical company.
- Acquisition of Laboratorios Casen Fleet S.L.U., a Spanish pharmaceutical company. Transaction closed in October.
- Full year 2013 targets updated.
- Interim 2013 dividend of € 0.22 per share to be distributed.

Milan, 30 October 2013 – The Board of Directors of Recordati S.p.A. approved the Group's consolidated results for the first nine months 2013 prepared in accordance with International Accounting Standards and International Financial Reporting Standards (IAS/IFRS) and in particular as per IAS 34 requirements for interim reporting. These financial statements will be available today at the company's offices and on the company's website:

http://www.recordati.com/rec_en/investors/reports/ and can also be viewed on the website of Borsa Italiana S.p.A.

Financial highlights

- **Consolidated revenue** in the first nine months 2013 is € 702.0 million, up by 13.2% compared to the same period of the preceding year. International sales grow by 16.5%.
- **EBITDA⁽¹⁾**, at 24.8% of sales, is € 174.0 million, an increase of 15.4% over the same period of the preceding year.
- **Operating income**, at 21.1% of sales, is € 148.3 million, an increase of 12.0% over the same period of the preceding year. Included is an € 8.0 million provision covering the completion of the sales force reorganization in the French subsidiary.
- **Net income**, at 14.5% of sales is € 101.5 million, an increase of 9.0% over the first nine months 2012.
- **Net financial position⁽²⁾** at 30 September 2013 records a net debt of € 133.3 million. During the period \$ 100.0 million (€ 75.0 million) were paid for the acquisition of a portfolio of products for the treatment of rare and other diseases, sold mainly in the U.S.A., from Lundbeck LLC, and

RECORDATI INDUSTRIA CHIMICA E FARMACEUTICA S.p.A.

Sede Legale
VIA M. CIVITALI, 1
20148 MILANO, ITALIA
TEL. (39) 0248787.1
FAX (39) 0240073747

CAPITALE SOCIALE € 26.140.644,50 I.V.
REG. IMP. MILANO N. 00748210150
CODICE FISCALE/P.IVA 007482210150
R.E.A. MILANO N. 401832

dividends were distributed for a total of € 20.1 million. **Shareholders' equity** increases to € 722.0 million.

⁽¹⁾ *Earnings before interest, taxes, depreciation and amortization.*

⁽²⁾ *Cash and short-term financial investments less bank overdrafts and medium/long-term loans which include the measurement at fair value of hedging derivatives (fair value hedge).*

Business development news

In January the acquisition of all rights concerning a portfolio of products indicated for the treatment of rare and other diseases and marketed mainly in the United States of America, from Lundbeck LLC. was successfully concluded. The value of the transaction is of \$ 100 million, of which \$ 80 million paid at the closing on January 18 and \$ 20 million in August. The acquired portfolio is now marketed in the U.S. by Recordati Rare Diseases Inc., a wholly-owned U.S. corporation. The main product in the portfolio is Panhematin[®] (haemin for injection) for the amelioration of recurrent attacks of acute intermittent porphyria. Other important drugs acquired are NeoProfen[®] (ibuprofen lysine injection), indicated to close a clinically significant patent ductus arteriosus (PDA) in premature infants, and Cosmegen[®] (dactinomycin for injection) used mainly in the treatment of three rare cancers.

During July the agreements covering the acquisition of 90% of the share capital of Opalia Pharma S.A., a Tunisian pharmaceutical company with headquarters in Ariana, a suburb of Tunis, were signed. The value of the transaction (enterprise value) is of around € 37 million and will be funded from existing liquidity. A partial closing of the transaction, involving the majority of the capital which is held by non-Tunisian shareholders, is expected to take place shortly. Opalia Pharma was established in 1988, ranks eighth in the Tunisian pharmaceutical market and is the third largest local pharmaceutical company. The company markets branded generic drugs with leading products in dermatology and in the gastrointestinal and respiratory therapeutic areas. Opalia manufactures most of its products in a modern, cGMP certified production facility specialized in liquid and semi-solid forms. The company employs around 320 people and generates annual sales of around TND 40 million (around € 18 million).

During September the agreements covering the acquisition of 100% of the share capital of Laboratorios Casen Fleet S.L.U., a Spanish pharmaceutical company with headquarters in Madrid and production facilities in Utebo, Zaragoza, were signed. The transaction was successfully concluded in October. The value of the transaction (enterprise value) is of € 93 million of which € 89.5 million were paid at the closing. Casen Fleet primarily markets internally developed drugs principally in the gastroenterological therapeutic area in Spain and Portugal through its own organisation and in other countries through partners. Approximately 55% of revenue is generated by a line of products used in the preparation for colonoscopy. The main product in this line is Citrafleet[®], already marketed by Recordati in Germany. The company's product portfolio also comprises oral rehydration products, probiotics and OTC brands for gynecological use. Approximately 80% of revenue is generated by private payers and is therefore outside public healthcare reimbursement schemes. Casen Fleet develops and manufactures most of its medicines in its own facility in Utebo, Zaragoza, which occupies an area of 23,165 sq. m. The company employs around 230 people and sales in 2012 are € 45.3 million.

Subsequent events and business outlook

During October the acquisition of 100% of the share capital of Laboratorios Casen Fleet S.L.U., a Spanish pharmaceutical company with headquarters in Madrid and production facilities in Utebo, Zaragoza, was successfully concluded. The value of the transaction (enterprise value) is of € 93 million

of which € 89.5 million were paid at the closing.

The group's business performance was in line with expectations during October. For the full year 2013, targets are to achieve sales of more than € 930 million, operating income of more than € 190 million and net income of more than € 132 million.

Further resolutions

2013 Interim dividend

The Board of Directors resolved to distribute an interim dividend relating to the financial year 2013 amounting to € 0.22 (before withholding tax) on each outstanding share, excluding shares in treasury stock. The interim dividend will be paid, through the authorised intermediaries, as from November 21, 2013 on coupon No. 12 to be presented on November 18, 2013.

The Independent Auditor's opinion on the distribution of the interim dividend is also available at the Company's registered offices as per article 2433-bis of the Italian Civil Code.

The Directors' Report and financial statements of Recordati S.p.A. as at 30 June 2013, on which the Board of Directors based its resolution to distribute the abovementioned interim dividend, are available at the Company's registered offices and published on the Company's website (www.recordati.com). Such documents may also be viewed on Borsa Italiana S.p.A.'s website.

Stock options granted

As per article 84-bis of Consob Regulation 11971/99 ("Issuers' Regulations") we furthermore inform that the Board of Directors, as proposed by the Remuneration Committee in its meeting of today, resolved to grant 360,000 stock options under the 2010-2013 Stock Option Plan approved by the Shareholders' Meeting of 13 April 2010, to 4 employees of Recordati S.p.A. and its subsidiaries (see table attached). The options may be exercised only if certain consolidated net income objectives are reached. The strike price, calculated by averaging the market price of the share over the period between the date of grant and the same day of the preceding month, is fixed at € 8.93 The characteristics of the plan are described in the information document issued on 5 March 2010 (the object of the third point of the Board's explanatory report on the 13 April 2010 Meeting's Agenda) and available on the company's website:

http://www.recordati.it/investors/regulated_information/stock_options.aspx?sc_lang=en

Conference call

Recordati will be hosting a *conference call* **today 30 October 2013** at 4.00 pm Italian time (3.00 pm London time, 10.00 am New York time). The dial-in numbers are:

Italy	+39 02 8058811, toll free 800 213 858
UK	+44 1 212818003, toll free 800 0156384
USA	+1 718 7058794, toll free 855 2656959
France	+33 170918703
Germany	+49 65 255114451

Callers are invited to dial-in 10 minutes before conference time. If conference operator assistance is required during the connection please digit * followed by 0 or call +39 02 8061371. A recording of the conference call will be placed on the website www.recordati.com.

A set of slides which will be referred to during the call will be available on our website www.recordati.com under Investors/Company Presentations.

Recordati, established in 1926, is an international pharmaceutical group, listed on the Italian Stock Exchange (Reuters RECI.MI, Bloomberg REC IM, ISIN IT 0003828271), with a total staff of over 3,300, dedicated to the research, development, manufacturing and marketing of pharmaceuticals. Headquartered in Milan, Italy, Recordati has operations in the main European countries, in Russia, in other Central and Eastern European countries, in Turkey and in the United States of America. A field force of more than 1,700 medical representatives promotes a wide range of innovative pharmaceuticals, both proprietary and under license, in a number of therapeutic areas including a specialized business dedicated to treatments for rare diseases. Recordati is a partner of choice for new product licenses for its territories. Recordati is committed to the research and development of new drug entities within the cardiovascular and urogenital therapeutic areas and of treatments for rare diseases. Consolidated revenue for 2012 was € 828.3 million, operating income was € 167.0 million and net income was € 118.5 million.

For further information:

Recordati website: www.recordati.com

Investor Relations

Marianne Tatschke
(39)0248787393
e-mail: inver@recordati.it

Media Relations

Ketchum
Cristina Risciotti, (39)0262411919, cristina.risciotti@ketchum.com
Marzia Ongaretti, (39)0262411915, marzia.ongaretti@ketchum.com

Statements contained in this release, other than historical facts, are "forward-looking statements" (as such term is defined in the Private Securities Litigation Reform Act of 1995). These statements are based on currently available information, on current best estimates, and on assumptions believed to be reasonable. This information, these estimates and assumptions may prove to be incomplete or erroneous, and involve numerous risks and uncertainties, beyond the Company's control. Hence, actual results may differ materially from those expressed or implied by such forward-looking statements. All mentions and descriptions of Recordati products are intended solely as information on the general nature of the company's activities and are not intended to indicate the advisability of administering any product in any particular instance.

RECORDATI GROUP

Summary of consolidated results prepared in accordance with the International Accounting Standards and International Financial Reporting Standards (IAS/IFRS)
(thousands of €)

INCOME STATEMENT	First nine months 2013	First nine months 2012	Change %
REVENUE	702,009	620,297	13.2
Cost of sales	(241,915)	(218,729)	10.6
GROSS PROFIT	460,094	401,568	14.6
Selling expenses	(205,987)	(188,095)	9.5
Research and development expenses	(55,390)	(44,456)	24.6
General & administrative expenses	(38,888)	(33,133)	17.4
Other income (expenses), net	(11,507)	(3,488)	229.9
OPERATING INCOME	148,322	132,396	12.0
Financial income (expenses), net	(10,569)	(4,230)	149.9
PRE-TAX INCOME	137,753	128,166	7.5
Provision for income taxes	(36,271)	(35,051)	3.5
NET INCOME	101,482	93,115	9.0
Attributable to:			
Equity holders of the parent	101,470	93,107	9.0
Minority interests	12	8	50.0

EARNINGS PER SHARE	First nine months 2013	First nine months 2012	Change %
Basic	€ 0.504	€ 0.467	7.9
Diluted	€ 0.479	€ 0.441	8.6

Earnings per share (EPS) are based on average shares outstanding during each year, 201,356,295 in 2013 and 199,484,434 in 2012, net of average treasury stock which amounted to 7,768,861 shares in 2013 and to 9,640,722 shares in 2012. Diluted earnings per share is calculated taking into account stock options granted to employees.

COMPOSITION OF REVENUE	First nine months 2013	First nine months 2012	Change %
Total revenue	702,009	620,297	13.2
Italy	173,125	166,452	4.0
International	528,884	453,845	16.5

RECORDATI GROUP

Summary of consolidated results prepared in accordance with the International Accounting Standards and International Financial Reporting Standards (IAS/IFRS)
(thousands of €)

INCOME STATEMENT	Third quarter 2013	Third quarter 2012	Change %
REVENUE	224,275	200,353	11.9
Cost of sales	(76,255)	(71,211)	7.1
GROSS PROFIT	148,020	129,142	14.6
Selling expenses	(62,932)	(59,107)	6.5
Research and development expenses	(17,441)	(15,682)	11.2
General & administrative expenses	(12,259)	(10,505)	16.7
Other income (expenses), net	(9,622)	(1,604)	499.9
OPERATING INCOME	45,766	42,244	8.3
Financial income (expenses), net	(3,716)	(1,816)	104.6
PRE-TAX INCOME	42,050	40,428	4.0
Provision for income taxes	(10,863)	(10,574)	2.7
NET INCOME	31,187	29,854	4.5
Attributable to:			
Equity holders of the parent	31,183	29,851	4.5
Minority interests	4	3	33.3

COMPOSITION OF REVENUE	Third quarter 2013	Third quarter 2012	Change %
Total revenue	224,275	200,353	11.9
Italy	49,563	48,891	1.4
International	174,712	151,462	15.4

RECORDATI GROUP

Summary of consolidated results prepared in accordance with the International Accounting Standards and International Financial Reporting Standards (IAS/IFRS)
(thousands of €)

ASSETS	30.09.2013	31.12.2012
Property, plant and equipment	61,150	59,972
Intangible assets	282,926	231,470
Goodwill	394,933	413,213
Equity investments	6,290	6,925
Non-current receivables	4,234	3,788
Deferred tax assets	25,223	22,837
TOTAL NON-CURRENT ASSETS	774,756	738,205
Inventories	132,923	126,388
Trade receivables	169,696	155,359
Other receivables	19,787	24,983
Other current assets	5,774	2,164
Fair value of hedging derivatives (fair value hedge)	0	1,371
Short-term financial investments, cash and cash equivalents	115,605	38,418
TOTAL CURRENT ASSETS	443,785	348,683
TOTAL ASSETS	1,218,541	1,086,888
EQUITY AND LIABILITIES	30.09.2013	31.12.2012
Share capital	26,141	26,141
Capital in excess of par value	83,719	83,719
Treasury stock	(41,386)	(46,254)
Hedging reserve	(3,182)	(4,983)
Translation reserve	(30,451)	(3,713)
Other reserves	25,810	26,326
Retained earnings	559,853	501,701
Net income for the year	101,470	118,484
Interim dividend	0	(40,077)
GROUP SHAREHOLDERS' EQUITY	721,974	661,344
Minority interest	65	53
SHAREHOLDERS' EQUITY	722,039	661,397
Loans due after one year	223,807	129,111
Employees' termination pay	17,579	17,862
Deferred tax liabilities	14,819	15,872
Other non-current liabilities	1,169	1,828
TOTAL NON-CURRENT LIABILITIES	257,374	164,673
Trade payables	109,434	106,926
Other payables	55,037	53,984
Tax liabilities	18,671	9,789
Other current liabilities	510	458
Provisions	27,166	20,544
Fair value of hedging derivatives (cash flow hedge)	3,182	4,983
Fair value of hedging derivatives (fair value hedge)	639	0
Loans due within one year	7,994	8,147
Bank overdrafts	16,495	55,987
TOTAL CURRENT LIABILITIES	239,128	260,818
TOTAL EQUITY AND LIABILITIES	1,218,541	1,086,888

DECLARATION BY THE MANAGER RESPONSIBLE FOR PREPARING THE COMPANY'S FINANCIAL REPORTS

The manager responsible for preparing the company's financial reports Fritz Squindo declares, pursuant to paragraph 2 of Article 154-*bis* of the Consolidated Law on Finance, that the accounting information contained in this press release corresponds to the document results, books and accounting records.

TABLE No. 1 of outline 7 of Annex 3A of Regulation No. 11971/1999

NAME OR CATEGORY	POSITION	FRAME 2							
		Stock Options							
		SECTION ONE							
		Options relating to currently valid plans, approved on the basis of previous shareholders' resolutions							
Date of the shareholders' resolution	Description of instrument	Options held as at 28 th October 2013	Options exercised since beginning of the plan until 28 th October 2013 ****	Date of grant by BoD	Exercise price €	Market price of the underlying financial instruments on the grant date (official price) €	Exercise period (from to) ***		
Giovanni Recordati	Chairman, CEO and General Manager *	06/04/2006	Options on Recordati S.p.A. shares with physical delivery	0	2006-2009 Plan: 525.000 2010-2013 Plan: 0	29/10/2008	4.073	3.783	9.05.2013 - 31.12.2013 (4 th tranche)
		06/04/2006	Options on Recordati S.p.A. shares with physical delivery	75,000		27/10/2009	4.87	5.1138	9.05.2013 - 31.12.2014 (3 rd tranche) 9.05.2014 - 31.12.2014 (4 th tranche)
		13/04/2010	Options on Recordati S.p.A. shares with physical delivery	360,000		09/02/2011	6.7505	6.77	2013** - 31.12.2019 (1 st tranche) 2014** - 31.12.2019 (2 nd tranche) 2015** - 31.12.2019 (3 rd tranche) 2016** - 31.12.2019 (4 th tranche)
		13/04/2010	Options on Recordati S.p.A. shares with physical delivery	360,000		08/05/2012	5.307	5.1824	2014** - 31.12.2020 (1 st tranche) 2015** - 31.12.2020 (2 nd tranche) 2016** - 31.12.2020 (3 rd tranche) 2017** - 31.12.2020 (4 th tranche)
Alberto Recordati	Vice Chairman *	06/04/2006	Options on Recordati S.p.A. shares with physical delivery	75,000	2006-2009 Plan: 112.500 2010-2013 Plan: 0	29/10/2008	4.073	3.783	9.05.2012 - 31.12.2013 (3 rd tranche) 9.05.2013 - 31.12.2013 (4 th tranche)
		06/04/2006	Options on Recordati S.p.A. shares with physical delivery	112,500		27/10/2009	4.87	5.1138	9.05.2012 - 31.12.2014 (2 nd tranche) 9.05.2013 - 31.12.2014 (3 rd tranche) 9.05.2014 - 31.12.2014 (4 th tranche)
		13/04/2010	Options on Recordati S.p.A. shares with physical delivery	180,000		09/02/2011	6.7505	6.77	2013** - 31.12.2019 (1 st tranche) 2014** - 31.12.2019 (2 nd tranche) 2015** - 31.12.2019 (3 rd tranche) 2016** - 31.12.2019 (4 th tranche)
		13/04/2010	Options on Recordati S.p.A. shares with physical delivery	180,000		08/05/2012	5.307	5.1824	2014** - 31.12.2020 (1 st tranche) 2015** - 31.12.2020 (2 nd tranche) 2016** - 31.12.2020 (3 rd tranche) 2017** - 31.12.2020 (4 th tranche)
Andrea Recordati	Director *	06/04/2006	Options on Recordati S.p.A. shares with physical delivery	0	2006-2009 Plan: 175.000	29/10/2008	4.073	3.783	9.05.2013 - 31.12.2013 (4 th tranche)

		06/04/2006	Options on Recordati S.p.A. shares with physical delivery	25,000	2010-2013 Plan: 0	27/10/2009	4.87	5.1138	9.05.2013 - 31.12.2014 (3 rd tranche) 9.05.2014 - 31.12.2014 (4 th tranche)
		13/04/2010	Options on Recordati S.p.A. shares with physical delivery	130,000		09/02/2011	6.7505	6.77	2013** - 31.12.2019 (1 st tranche) 2014** - 31.12.2019 (2 nd tranche) 2015** - 31.12.2019 (3 rd tranche) 2016** - 31.12.2019 (4 th tranche)
		13/04/2010	Options on Recordati S.p.A. shares with physical delivery	130,000		08/05/2012	5.307	5.1824	2014** - 31.12.2020 (1 st tranche) 2015** - 31.12.2020 (2 nd tranche) 2016** - 31.12.2020 (3 rd tranche) 2017** - 31.12.2020 (4 th tranche)
Fritz Squindo	Director *	06/04/2006	Options on Recordati S.p.A. shares with physical delivery	32,500	2006-2009 Plan: 117.500 2010-2013 Plan: 0	29/10/2008	4.073	3.783	9.05.2011 - 31.12.2013 (2 nd tranche) 9.05.2012 - 31.12.2013 (3 rd tranche) 9.05.2013 - 31.12.2013 (4 th tranche)
		06/04/2006	Options on Recordati S.p.A. shares with physical delivery	150,000		27/10/2009	4.87	5.1138	9.05.2011 - 31.12.2014 (2 nd tranche) 9.05.2012 - 31.12.2014 (2 nd tranche) 9.05.2013 - 31.12.2014 (3 rd tranche) 9.05.2014 - 31.12.2014 (4 th tranche)
		13/04/2010	Options on Recordati S.p.A. shares with physical delivery	180,000		09/02/2011	6.7505	6.77	2013** - 31.12.2019 (1 st tranche) 2014** - 31.12.2019 (2 nd tranche) 2015** - 31.12.2019 (3 rd tranche) 2016** - 31.12.2019 (4 th tranche)
		13/04/2010	Options on Recordati S.p.A. shares with physical delivery	180,000		08/05/2012	5.307	5.1824	2014** - 31.12.2020 (1 st tranche) 2015** - 31.12.2020 (2 nd tranche) 2016** - 31.12.2020 (3 rd tranche) 2017** - 31.12.2020 (4 th tranche)

* This person is a beneficiary of stock option plans not as a member of the Board of Directors of Recordati S.p.A., but as member of the key management personnel of the Company.

** Thirty days following the shareholders meeting held to approve the annual report of the previous year.

*** Tranches of options which have already vested and which have not yet been exercised subsequent to vesting may be exercised before and not later than the end of the fifth (2006-2009)/eighth (2010-2013 Plan) financial year following that in which the Board of Directors granted the options. Furthermore, each tranche consists of 25% of the options granted to the participant.

**** Options of expired granting are excluded.

TABLE No. 1 of outline 7 of Annex 3A of Regulation No. 11971/1999

NAME OR CATEGORY	POSITION	FRAME 2							
		OPTIONS (option grant)							
		SECTION ONE							
		Options relating to currently valid plans, approved on the basis of previous shareholders' resolutions							
Date of the shareholders' resolution	Description of instrument	Options held as at 28 th October 2013	Options exercised since beginning of the plan until 28 th October 2013***	Date of grant by BoD	Exercise price €	Market price of the underlying financial instruments on the grant date (official price) €	Exercise period (from to) *		
N. 2 key management personnel		06/04/2006	Options on Recordati S.p.A. shares with physical delivery	0	2006-2009 Plan: 210.000 2010-2013 Plan: 37.500	29/10/2008	4.073	3.783	9.05.2013 - 31.12.2013 (4 th tranche)
		06/04/2006	Options on Recordati S.p.A. shares with physical delivery	30,000		27/10/2009	4.87	5.1138	9.05.2012 - 31.12.2014 (2 nd tranche) 9.05.2013 - 31.12.2013 (3 rd tranche) 9.05.2014 - 31.12.2014 (4 th tranche)
		13/04/2010	Options on Recordati S.p.A. shares with physical delivery	112,500		09/02/2011	6.7505	6.77	2013** - 31.12.2019 (1 st tranche) 2014** - 31.12.2019 (2 nd tranche) 2015** - 31.12.2019 (3 rd tranche) 2016** - 31.12.2019 (4 th tranche)
		13/04/2010	Options on Recordati S.p.A. shares with physical delivery	270,000		08/05/2012	5.307	5.1824	2014** - 31.12.2020 (1 st tranche) 2015** - 31.12.2020 (2 nd tranche) 2016** - 31.12.2020 (3 rd tranche) 2017** - 31.12.2020 (4 th tranche)
Other senior managers		06/04/2006	Options on Recordati S.p.A. shares with physical delivery	140,000	2006-2009 Plan: 4.360.000 2010-2013 Plan: 627.500	29/10/2008	4.073	3.783	9.05.2012-31.12.2013 (3 rd tranche) 9.05.2013- 31.12.2013 (4 th tranche)
		06/04/2006	Options on Recordati S.p.A. shares with physical delivery	10,000		11/02/2009	3.894	4.0796	9.05.2012-31.12.2013 (3 rd tranche) 9.05.2013 - 31.12.2013 (4 th tranche)
		06/04/2006	Options on Recordati S.p.A. shares with physical delivery	835,000		27/10/2009	4.87	5.1138	9.05.2012 - 31.12.2014 (2 nd tranche) 9.05.2013 - 31.12.2014 (3 rd tranche) 9.05.2014 - 31.12.2014 (4 th tranche)
		13/04/2010	Options on Recordati S.p.A. shares with physical delivery	2,087,500		09/02/2011	6.7505	6.77	2013** - 31.12.2019 (1 st tranche) 2014** - 31.12.2019 (2 nd tranche) 2015** - 31.12.2019 (3 rd tranche) 2016** - 31.12.2019 (4 th tranche)
		13/04/2010	Options on Recordati S.p.A. shares with physical delivery	3,060,000		08/05/2012	5.307	5.1824	2014** - 31.12.2020 (1 st tranche) 2015** - 31.12.2020 (2 nd tranche) 2016** - 31.12.2020 (3 rd tranche) 2017** - 31.12.2020 (4 th tranche)

TABLE No. 1 of outline 7 of Annex 3A of Regulation No. 11971/1999

NAME OR CATEGORY	POSITION	FRAME 2						
		OPTIONS (option grant)						
		SECTION TWO						
		Newly assigned options on the basis of a decision of the Board of Directors to implement the shareholders' resolution, as recommended by the Remuneration Committee						
		Date of shareholder resolution	Description of the instrument	Number of options	Date of grant by the Board of Directors	Exercise Price (€)	Market price of the financial instruments on the grant date (official price) * €	Exercise period (**)
Other senior managers		13/04/2010	Options on Recordati S.p.A. shares with physical delivery	360,000	30/10/2013 (30/10/2013 Remuneration Committee)	8.93	9.4005	2015*** - 31.12.2021 (1 st tranche) 2016*** - 31.12.2021 (2 nd tranche) 2017*** - 31.12.2021 (3 rd tranche) 2018*** - 31.12.2021 (4 th tranche)
* Official price on the day before the grant date: (29 th October 2013) ** Each tranche consists of 25% of the options granted to the participant. *** Thirty days following the shareholders meeting held to approve the annual report of the previous year.								